Aloradine

Drug Profile

Aloradine

Alternative Names: Aloradine IN; Aloradine NS; PH94B; PH94B NS

Latest Information Update: 03 Dec 2015

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Pherin Pharmaceuticals
  • Class Anxiolytics; Small molecules
  • Mechanism of Action Sensory receptor cell modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase III Social phobia

Most Recent Events

  • 18 Feb 2015 Pherin Pharmaceuticals has patent protection for Aloradine in USA, Australia, Canada, China, Denmark, France, Germany, Great Britain, Ireland, Italy, Japan, Mexico, Netherlands, South Korea, Spain, Sweden and Switzerland
  • 18 Feb 2015 Efficacy and adverse events data from a phase III trial in Social phobia released by Pherin Pharmaceuticals
  • 18 Feb 2015 Pherin Pharmaceuticals plans a phase III trial in Social phobia in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top